Ambros Therapeutics, headquartered in Irvine, California, is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with a high unmet medical need.
Our lead investigational program targets complex regional pain syndrome type 1 (CRPS-1), a devastating rare metabolic bone disease that causes severe, unrelenting and frequently lasting pain following trauma to the bone or an injury. Patients may experience significant functional loss, sleep disturbance, and meaningful diminished quality of life and independence.
The Phase 3 pivotal trial (CRPS-RISE) represents a first-in-class approach to addressing a disease with no FDA-approved medicines.

We center patients' lived experiences in our decisions, translating their perspectives into bold goals and measurable impact, uniting diverse expertise to co-create solutions that are creative, impactful, and executable. Guided by principles of integrity, collaboration, and trust, we uphold the highest ethical and scientific standards, delivering on our commitments with transparency and accountability.

We work as if each patient is counting on us—because they are.